Next Article in Journal
Comparative Radioimmunotherapy of Experimental Melanoma with Novel Humanized Antibody to Melanin Labeled with 213Bismuth and 177Lutetium
Previous Article in Journal
Drug Delivery Systems for Vitamin D Supplementation and Therapy
Previous Article in Special Issue
Neuronanomedicine: An Up-to-Date Overview
Article Menu
Issue 7 (July) cover image

Export Article

Open AccessCommunication

Brain Delivery of Thyrotropin-Releasing Hormone via a Novel Prodrug Approach

1
Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX 76107, USA
2
School of Pharmacy, The University of Queensland, Brisbane, QLD 4072, Australia
3
School of Chemistry & Molecular Biosciences, The University of Queensland, St Lucia, QLD 4072, Australia
*
Author to whom correspondence should be addressed.
Pharmaceutics 2019, 11(7), 349; https://doi.org/10.3390/pharmaceutics11070349
Received: 18 June 2019 / Revised: 14 July 2019 / Accepted: 16 July 2019 / Published: 18 July 2019
(This article belongs to the Special Issue Drug Delivery to the Brain)
  |  
PDF [1388 KB, uploaded 18 July 2019]
  |  

Abstract

Using thyrotropin-releasing hormone (TRH) as a model, we explored whether synergistic combination of lipoamino acid(s) and a linker cleaved by prolyl oligopeptidase (POP) can be used as a promoiety for prodrug design for the preferential brain delivery of the peptide. A representative prodrug based on this design principle was synthesized, and its membrane affinity and in vitro metabolic stability, with or without the presence of a POP inhibitor, were studied. The in vivo formation of TRH from the prodrug construct was probed by utilizing the antidepressant effect of the peptide, as well as its ability to increase acetylcholine (ACh) synthesis and release. We found that the prototype prodrug showed excellent membrane affinity and greatly increased metabolic stability in mouse blood and brain homogenate compared to the parent peptide, yet a POP inhibitor completely prevented prodrug metabolism in brain homogenate. In vivo, administration of the prodrug triggered antidepressant-like effect, and microdialysis sampling showed greatly increased ACh release that was also antagonized upon a POP inhibitor treatment. Altogether, the obtained promising exploratory data warrant further investigations on the utility of the prodrug approach introduced here for brain-enhanced delivery of small peptides with neurotherapeutic potential. View Full-Text
Keywords: TRH; brain-targeting prodrug design; prolyl oligopeptides (POP); lipoamino acid; CNS-drug delivery TRH; brain-targeting prodrug design; prolyl oligopeptides (POP); lipoamino acid; CNS-drug delivery
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Prokai-Tatrai, K.; De La Cruz, D.L.; Nguyen, V.; Ross, B.P.; Toth, I.; Prokai, L. Brain Delivery of Thyrotropin-Releasing Hormone via a Novel Prodrug Approach. Pharmaceutics 2019, 11, 349.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Pharmaceutics EISSN 1999-4923 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top